Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.
Ori MagenJacob G WaxmanMaya Makov-AssifRoni VeredDror DickerMiguel A HernánMarc LipsitchBen Y ReisRan D BalicerNoa DaganPublished in: The New England journal of medicine (2022)
A fourth dose of the BNT162b2 vaccine was effective in reducing the short-term risk of Covid-19-related outcomes among persons who had received a third dose at least 4 months earlier. (Funded by the Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute.).